BioLineRx (BLRX) Non-Current Assets (2012 - 2025)

BioLineRx's Non-Current Assets history runs 14 years deep, the most recent figure standing at $17.2 million for Q4 2025.

• In Q4 2025, Non-Current Assets rose 45.94% year-over-year to $17.2 million; the TTM figure through Dec 2025 stood at $17.2 million (up 45.94% YoY), while the FY2025 annual figure was $17.2 million, up 45.94% from the prior year.
• Non-Current Assets was $17.2 million for Q4 2025 at BioLineRx, up from $11.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $24.4 million in Q4 2022 to a low of $11.3 million in Q3 2025.
• Historically, Non-Current Assets has averaged $19.6 million across 5 years, with a median of $23.7 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets plunged 38.07% in 2024, then soared 45.94% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $24.0 million in 2021, then advanced by 1.65% to $24.4 million in 2022, then plunged by 31.34% to $16.7 million in 2023, then decreased by 29.51% to $11.8 million in 2024, then jumped by 45.94% to $17.2 million in 2025.
• The last three Non-Current Assets figures came in at $17.2 million (Q4 2025), $11.3 million (Q3 2025), and $11.4 million (Q2 2025), per Business Quant data.